Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565297 | 1.00 | PNMT (0.53) | PNMTHTR2AHTR2CHTR2BS1PR1 | |
| SCHEMBL8297212 | 0.81 | OXTR (0.55) | PNMTHTR2AHTR2CHTR2BMAP3K14 | |
| SCHEMBL19657715 | 0.80 | S1PR1 (0.38) | PNMTS1PR1S1PR3ACHE | |
| SCHEMBL17927769 | 0.79 | FABP6 (0.49) | HTR2CS1PR1S1PR3ACHERIPK1 | |
| SCHEMBL2983125 | 0.79 | PNMT (0.53) | PNMTS1PR1S1PR3ACHEAHR | |
| SCHEMBL31111402 | 0.79 | MAPT (0.54) | PNMTS1PR1S1PR3ACHERIPK1 | |
| SCHEMBL30644265 | 0.79 | PNMT (0.53) | PNMTS1PR1S1PR3ACHEAHR | |
| SCHEMBL2060626 | 0.79 | MAPT (0.44) | S1PR1S1PR3ACHE | |
| SCHEMBL8061138 | 0.79 | MAPT (0.54) | PNMTS1PR1S1PR3ACHERIPK1 | |
| Hydrochloric Acid SCHEMBL7485797 | 0.77 | GAA (0.47) | S1PR1S1PR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | PNMT 259/4885HTR2A 4837/4885HTR2C 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.